Evolva Holding SA (ELVAF)
USD 0.9
(0.0%)
USD 0.9
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.83 Million CHF | -158.89% |
| 2022 | 9.91 Million CHF | 6243.0% |
| 2021 | -161.4 Thousand CHF | 98.48% |
| 2020 | -10.64 Million CHF | 68.49% |
| 2019 | -33.79 Million CHF | 40.93% |
| 2018 | -57.2 Million CHF | 39.15% |
| 2017 | -94 Million CHF | -118.74% |
| 2016 | -42.97 Million CHF | 44.99% |
| 2015 | -78.12 Million CHF | -46.61% |
| 2014 | -53.28 Million CHF | -185.17% |
| 2013 | -18.68 Million CHF | -105.22% |
| 2012 | -9.1 Million CHF | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 FY | -5.83 Million CHF | -158.89% |
| 2023 Q3 | -5.83 Million CHF | -147.38% |
| 2023 Q2 | 12.32 Million CHF | 1.92% |
| 2023 Q1 | 12.09 Million CHF | 21.95% |
| 2023 Q4 | -5.83 Million CHF | 0.0% |
| 2022 Q1 | 4.13 Million CHF | 2662.99% |
| 2022 FY | 9.91 Million CHF | 6243.0% |
| 2022 Q3 | 9.25 Million CHF | 86.96% |
| 2022 Q4 | 9.91 Million CHF | 7.17% |
| 2022 Q2 | 4.94 Million CHF | 19.7% |
| 2021 Q3 | -995.8 Thousand CHF | -181.18% |
| 2021 Q4 | -161.3 Thousand CHF | 83.8% |
| 2021 FY | -161.4 Thousand CHF | 98.48% |
| 2021 Q1 | 216 Thousand CHF | 102.03% |
| 2021 Q2 | 1.22 Million CHF | 467.87% |
| 2020 Q3 | -11.7 Million CHF | 40.33% |
| 2020 Q4 | -10.64 Million CHF | 9.05% |
| 2020 FY | -10.64 Million CHF | 68.49% |
| 2020 Q1 | -20.78 Million CHF | 38.48% |
| 2020 Q2 | -19.61 Million CHF | 5.64% |
| 2019 Q1 | -40 Million CHF | 31.01% |
| 2019 Q4 | -33.79 Million CHF | 3.68% |
| 2019 Q2 | -38.69 Million CHF | 3.28% |
| 2019 FY | -33.79 Million CHF | 40.93% |
| 2019 Q3 | -35.07 Million CHF | 9.34% |
| 2018 Q4 | -57.98 Million CHF | 0.0% |
| 2018 Q2 | -72.29 Million CHF | 0.0% |
| 2018 Q1 | -72.29 Million CHF | 23.73% |
| 2018 FY | -57.2 Million CHF | 39.15% |
| 2018 Q3 | -57.98 Million CHF | 19.79% |
| 2017 Q2 | -30.56 Million CHF | 0.0% |
| 2017 FY | -94 Million CHF | -118.74% |
| 2017 Q3 | -94.78 Million CHF | -210.15% |
| 2017 Q4 | -94.78 Million CHF | 0.0% |
| 2017 Q1 | -30.56 Million CHF | 30.47% |
| 2016 Q4 | -43.95 Million CHF | 0.0% |
| 2016 FY | -42.97 Million CHF | 44.99% |
| 2016 Q3 | -43.95 Million CHF | 30.05% |
| 2016 Q2 | -62.83 Million CHF | 0.0% |
| 2016 Q1 | -62.83 Million CHF | 20.56% |
| 2015 FY | -78.12 Million CHF | -46.61% |
| 2015 Q1 | -39.32 Million CHF | 26.19% |
| 2015 Q2 | -39.32 Million CHF | 0.0% |
| 2015 Q4 | -79.09 Million CHF | 0.0% |
| 2015 Q3 | -79.09 Million CHF | -101.11% |
| 2014 Q4 | -53.28 Million CHF | 0.0% |
| 2014 Q1 | -54.14 Million CHF | -189.77% |
| 2014 Q2 | -54.14 Million CHF | 0.0% |
| 2014 Q3 | -53.28 Million CHF | 1.59% |
| 2014 FY | -53.28 Million CHF | -185.17% |
| 2013 Q4 | -18.68 Million CHF | 0.0% |
| 2013 Q1 | -23.61 Million CHF | -159.35% |
| 2013 FY | -18.68 Million CHF | -105.22% |
| 2013 Q2 | -23.61 Million CHF | 0.0% |
| 2013 Q3 | -18.68 Million CHF | 20.87% |
| 2012 FY | -9.1 Million CHF | 0.0% |
| 2012 Q4 | -9.1 Million CHF | 0.0% |
| 2012 Q3 | -9.1 Million CHF | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -445602.29% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 7.389% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 1038.149% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -2239.035% |
| Qrons Inc. | 351.42 Thousand USD | 1761.426% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1019.239% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 113.644% |
| BioStem Technologies, Inc. | 4.47 Million USD | 230.561% |
| Skye Bioscience, Inc. | -5.72 Million USD | -2.05% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -28509.859% |
| Rebus Holdings, Inc. | 305 Thousand USD | 2014.328% |
| CSL Limited | 10.52 Billion USD | 100.055% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 113.443% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 128.796% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 29488.936% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 203.37% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 137.041% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 241.784% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 1552.959% |
| SQZ Biotechnologies Company | -36.23 Million USD | 83.888% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 360.397% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 729.723% |
| Mesoblast Limited | 55.85 Million USD | 110.453% |
| Marizyme, Inc. | 18.56 Million USD | 131.443% |
| Genus plc | 190.6 Million USD | 103.063% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 361.142% |
| Pharming Group N.V. | 109.8 Million USD | 105.317% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 778.728% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 580.992% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 958.632% |
| ContraFect Corporation | -6.02 Million USD | 3.108% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 4436.559% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 605.327% |
| IMV Inc. | 7.67 Million USD | 176.119% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 206.122% |
| MultiCell Technologies, Inc. | 90.04 USD | 6484662.417% |
| ONE Bio Corp. | 9.04 Million USD | 164.587% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -695.487% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 145.1% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 526.815% |
| Q BioMed Inc. | 4.06 Million USD | 243.81% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 119.109% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 679.399% |
| Biomind Labs Inc. | 711.4 Thousand USD | 920.731% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 109.643% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 392.024% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 145.591% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 1723.169% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 4276.347% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 365.157% |
| GB Sciences, Inc. | 1.74 Million USD | 434.152% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -3076.867% |
| HST Global, Inc. | 96.79 Thousand USD | 6132.151% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 2931.338% |
| Halberd Corporation | 144.72 Thousand USD | 4134.452% |
| Enzolytics Inc. | 981.65 Thousand USD | 694.781% |
| Agentix Corp. | 37.63 Thousand USD | 15615.665% |
| Resverlogix Corp. | 6.45 Million USD | 190.508% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -767.448% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.712% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 87.58% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 182.573% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 315.56% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 33.951% |
| AVAX Technologies, Inc. | -5.9 Million USD | 1.093% |
| Zenith Capital Corp. | 10.06 Thousand USD | 58115.7% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.45% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 3013.058% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 344.703% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 3649.168% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -31774.113% |
| Kadimastem Ltd | -253.1 Thousand USD | -2206.857% |
| Helix BioMedix, Inc. | -2.57 Million USD | -127.184% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 3001.16% |
| LadRx Corporation | -2.03 Million USD | -186.707% |
| Cell Source, Inc. | 9.23 Million USD | 163.244% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1019.239% |
| NovAccess Global Inc. | 2.17 Million USD | 368.019% |
| Affymax, Inc. | -5.59 Million USD | -4.318% |
| Itoco Inc. | 228.3 Thousand USD | 2657.412% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 4393.509% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 217.787% |
| Mobile Lads Corp. | 484.23 Thousand USD | 1305.765% |
| CytoDyn Inc. | 20.26 Million USD | 128.816% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -902326.584% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -62896.178% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 175.768% |
| SYBLEU INC | 473.71 Thousand USD | 1332.537% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 231.0% |
| International Stem Cell Corporation | 2.59 Million USD | 325.432% |
| Bioxytran, Inc. | 1.89 Million USD | 407.476% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 9454.942% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 367.72% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 270.026% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 168.265% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 855.714% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -367.096% |
| Neutra Corp. | 52.18 Thousand USD | 11288.035% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -134.58% |
| PureTech Health plc | -167.19 Million USD | 96.508% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -2284.038% |
| IXICO plc | -4.44 Million USD | -31.367% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 144.169% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 110.645% |
| CSL Limited | 10.52 Billion USD | 100.055% |
| Cellectis S.A. | -43.81 Million USD | 86.675% |